BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 969 filers reported holding BAXTER INTL INC in Q3 2017. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $345,000 | +5.2% | 4,670 | -7.5% | 0.32% | +6.7% |
Q1 2018 | $328,000 | -51.3% | 5,050 | -51.5% | 0.30% | -48.4% |
Q4 2017 | $673,000 | -33.0% | 10,410 | -35.0% | 0.58% | -62.3% |
Q3 2017 | $1,004,000 | -89.9% | 16,005 | -90.2% | 1.54% | -27.3% |
Q2 2017 | $9,937,000 | +142.3% | 164,135 | +107.6% | 2.12% | +129.8% |
Q1 2017 | $4,101,000 | +37181.8% | 79,070 | +30907.8% | 0.92% | +30666.7% |
Q4 2016 | $11,000 | -96.0% | 255 | -95.6% | 0.00% | -95.5% |
Q3 2016 | $277,000 | -92.4% | 5,820 | -92.8% | 0.07% | -92.7% |
Q2 2016 | $3,633,000 | – | 80,350 | – | 0.90% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GENERATION INVESTMENT MANAGEMENT LLP | 21,171,371 | $1,817,350,000 | 7.47% |
Soditic Asset Management LLP | 147,620 | $12,672,000 | 6.53% |
NUANCE INVESTMENTS, LLC | 4,084,218 | $350,589,000 | 6.17% |
PRAGMA GESTAO DE PATRIMONIO LTD | 145,000 | $12,447 | 5.96% |
Veritas Asset Management LLP | 12,222,261 | $1,049,159,000 | 5.89% |
Pavadi Capital LLC | 72,782 | $6,248,000 | 4.74% |
Sonen Capital LLC | 48,907 | $4,198,000 | 4.06% |
Glenview Capital Management | 2,182,422 | $187,339,000 | 3.99% |
Dash Acquisitions Inc. | 103,963 | $8,924,000 | 3.87% |
Avidity Partners Management LP | 1,765,000 | $151,508,000 | 3.21% |